¼¼°èÀÇ TIL Ä¡·á ½ÃÀå : ½ÃÀå ºÐ¼® ¹× ¿¹Ãø - À¯Çüº°, Á¦Ç°º°, ¼­ºñ½ºº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, ÇÁ·Î¼¼½ºº°, ½ºÅ×ÀÌÁöº°, ¼Ö·ç¼Çº°(-2034³â)
TIL Therapy Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Application, End User, Process, Stage, Solutions
»óǰÄÚµå : 1813576
¸®¼­Ä¡»ç : Global Insight Services
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 324 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,750 £Ü 6,831,000
Single User License help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇϸç, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 5,750 £Ü 8,270,000
Site License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(±¹°¡)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,750 £Ü 9,708,000
Enterprise License help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ Àü ¼¼°è ¸ðµçºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ TIL Ä¡·á ½ÃÀå ±Ô¸ð´Â 2024³â 4¾ï ´Þ·¯¿¡¼­ 2034³â 61¾ï ´Þ·¯·Î È®´ëµÉ Àü¸ÁÀ̸ç, ¾à 31.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. TIL Ä¡·á ½ÃÀå¿¡´Â Á¾¾ç ħÀ± ¸²ÇÁ±¸¸¦ ÀÌ¿ëÇÏ´Â Ä¡·á°¡ Æ÷ÇԵ˴ϴÙ. Á¾¾ç ħÀ± ¸²ÇÁ±¸´Â ȯÀÚÀÇ Á¾¾ç¿¡¼­ ÃßÃâµÈ ¸é¿ª¼¼Æ÷·Î ½ÃÇè°ü ³»¿¡¼­ È®´ëµÇ¾î ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÀçÁÖÀԵ˴ϴÙ. ÀÌ ¸ÂÃãÇü ¸é¿ª Ä¡·á´Â ½ÅüÀÇ ÀÚ¿¬ÀûÀÎ Ç× Á¾¾ç ¹ÝÀÀÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¾Ï ÀÌȯÀ² Áõ°¡ ¹× ¼¼Æ÷ Ä¡·á ±â¼úÀÇ Áøº¸°¡ È¿´É Çâ»ó, ºñ¿ë Àý°¨, ÀÓ»ó ¿ëµµ È®´ë¿¡ ÃÊÁ¡À» ¸ÂÃß°í ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

TIL Ä¡·á ½ÃÀåÀº °³º°È­ ¾Ï Ä¡·á Á¢±ÙÀÇ Áøº¸¿¡ °ßÀÎµÇ¾î °­·ÂÇÑ È®ÀåÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù. Èæ»öÁ¾ ºÎ¹®Àº TIL Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÌ ³ô°í ±¤¹üÀ§ÇÑ Á¶»çÀÇ µÞ¹ÞħÀ¸·Î ÀÎÇØ ¼º°ú¸¦ À̲ø°í ÀÖ½À´Ï´Ù. ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC)Àº ÀÓ»ó½ÃÇè Áõ°¡ ¹× À¯¸ÁÇÑ ¿¹ºñ °á°úÀÇ ÇýÅÃÀ» ¹Þ¾Æ µÎ ¹øÂ°·Î ³ôÀº ½ÇÀûÀ» ¿Ã¸®°í ÀÖ½À´Ï´Ù. Èæ»öÁ¾ÀÇ ÇÏÀ§ ºÎ¹®Àº Ãʱ⠴ܰèÀÇ Ä¡·á¸¦ À¯¸Á½ÃÇϰí ȯÀÚÀÇ ¿¹ÈÄ¿Í »ýÁ¸À²À» Çâ»ó½Ãŵ´Ï´Ù. ÷´Ü ´Ü°èÀÇ Ä¡·áµµ ¼º°ø »ç·Ê Áõ°¡¿¡ °ßÀÎµÇ¾î °ßÀηÂÀ» Áõ°¡Çϰí ÀÖ½À´Ï´Ù. NSCLC ÇÏÀ§ ºÎ¹®¿¡¼­´Â Ç¥Àû Ä¡·áÀÇ Áøº¸·Î ƯÁ¤ À¯ÀüÀÚ ¸¶Ä¿¸¦ °¡Áø ȯÀÚ°¡ ÁÖ¿ä ¼öÇýÀÚ°¡ µÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß ÅõÀÚ´Â TIL äÃë ±â¼úÀÇ Çâ»ó°ú ¼¼Æ÷ Áõ½Ä °úÁ¤ÀÇ °­È­¿¡ ÁßÁ¡À» µÎ°í ½ÃÀåÀ» ÀüÁø½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±ÔÁ¦ »óȲÀÌ ÁøÈ­ÇÔ¿¡ µû¶ó ½ÂÀÎ °æ·ÎÀÇ ÇÕ¸®È­´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ°í ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí Ä¡·á ¿É¼ÇÀ» È®´ëÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­
À¯Çüº° ÀÚ°¡ TIL Ä¡·á, µ¿Á¾ TIL Ä¡·á
Á¦Ç°º° ¼¼Æ÷ ¹è¾ç ¹èÁö, ½Ã¾à, ŰƮ, Àåºñ, ¼ÒÇÁÆ®¿þ¾î
¼­ºñ½ºº° Á¦Á¶, ǰÁú °ü¸®, ÄÁ¼³ÆÃ, ¹°·ù
±â¼úº° À¯Àü °øÇÐ, ¼¼Æ÷ ¹è¾ç, µ¿°áº¸Á¸, »ý¹° ¹ÝÀÀ±â
¿ëµµº° Á¾¾çÇÐ, Ç÷¾×ÇÐ, °íÇü Á¾¾ç, Èñ±ÍÁúȯ
ÃÖÁ¾ »ç¿ëÀÚº° º´¿ø, Àü¹® Ŭ¸®´Ð, ¿¬±¸ ±â°ü, ¹ÙÀÌ¿À Á¦¾à ȸ»ç
ÇÁ·Î¼¼½ºº° ºÐ¸®, ÆØÃ¢, Ȱ¼ºÈ­, ÁÖÀÔ
½ºÅ×ÀÌÁöº° ÀüÀÓ»ó, ÀÓ»ó, »ó¾÷
¼Ö·ç¼Çº° ÅÏŰ ¼Ö·ç¼Ç, ¸ÂÃã ¼Ö·ç¼Ç, ÅëÇÕ ¼Ö·ç¼Ç

½ÃÀå ÇöȲ

TIL Ä¡·á ½ÃÀåÀº ÁøÈ­ÇÏ´Â ½ÃÀå Á¡À¯À²°ú Àü·«Àû °¡°Ý ¸ðµ¨À» Ư¡À¸·Î ÇÏ´Â ¿ªµ¿ÀûÀÎ »óȲÀ» °æÇèÇϰí ÀÖ½À´Ï´Ù. ¸é¿ª Ä¡·á ±â¼úÀÇ Áøº¸·Î ½ÅÁ¦Ç° Ãâ½Ã°¡ ½ÃÀåÀ» Ȱ¼ºÈ­Çϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â Çõ½ÅÀûÀÎ Ä¡·á¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÀïȯ°æÀº °¢ ȸ»ç°¡ µ¶ÀÚÀûÀÎ Á¦Ç°°ú Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ Â÷º°È­¸¦ µµ¸ðÇϵµ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù. °¡°Ý Àü·«Àº ºñ¿ë È¿°ú¿Í ȯÀÚ Áß½ÉÀÇ Ä¡·á°¡ Á߽õǴ µ¿¾È °¡Ä¡ ±â¹Ý ¸ðµ¨ÀÇ ¿µÇâÀ» ¹Þ½À´Ï´Ù. TIL Ä¡·á ½ÃÀå °æÀï ±¸µµ´Â ÁÖ¿ä ±â¾÷ °£ÀÇ °Ý·ÄÇÑ Àû´ë °ü°è¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. °¢ ȸ»ç´Â ±â¼ú Çõ½Å°ú Àü·«Àû ÆÄÆ®³Ê½ÊÀ» Ȱ¿ëÇϸ鼭 °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ º¥Ä¡¸¶Å·À» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå ¿ªÇп¡ Å©°Ô ¿µÇâÀ» ¹ÌÄ¡¸ç, ¾ö°ÝÇÑ ÁöħÀÌ Á¦Ç° °³¹ß ¹× ½ÂÀÎ ÇÁ·Î¼¼½º¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´ÀÇ ±ÔÁ¦ »óȲÀº ƯÈ÷ ¿µÇâÀÌ Å©¸ç ½ÃÀå ÁøÀÔ°ú È®´ë Àü·«¿¡ ´Þ·Á ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ ÁøÈ­ÇÔ¿¡ µû¶ó Áö¼ÓÀûÀÎ ¼ºÀå°ú °æÀï·ÂÀ» À¯ÁöÇϱâ À§Çؼ­´Â ±ÔÁ¦ Áؼö¿Í Àü·«Àû ¹Îø¼ºÀÌ ¿©ÀüÈ÷ Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä µ¿Çâ ¹× ¼ºÀå ÃËÁø¿äÀÎ :

TIL Ä¡·á ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á ¹× ¸é¿ª ¿ä¹ýÀÇ Áøº¸¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¹ýÀº ƯÁ¤ ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î ÇÏ°í °Ç°­ÇÑ Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÁöÁö¸¦ ¸ðÀ¸°í ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº À¯ÀüÀÚ °øÇаú º´¿ë ¿ä¹ýÀ» Ȱ¿ëÇÏ¿© TIL Ä¡·áÀÇ È¿´ÉÀ» ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿À±â¼ú°ú ¾Ï ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ¹Î°£ ´Üü´Â Çõ½ÅÀûÀÎ ¾Ï Ä¡·á¸¦ °³¹ßÇϱâ À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÚ±ÝÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀçÁ¤ Áö¿øÀº ÀÓ»ó½ÃÇè ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» °¡¼ÓÈ­ÇÏ°í ½ÃÀå ¿ªÇÐÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¼¼°èÀûÀÎ ¾Ï ÀÌȯÀ²ÀÇ »ó½Âµµ Å« ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀÔ´Ï´Ù. ȯÀÚ¿Í ÀÇ·á Á¦°ø¾÷ü´Â À¯¸ÁÇÑ ÀÓ»ó °á°ú·Î TIL Ä¡·áÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀǷḦ ÇâÇÑ µ¿ÇâÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í ÀÖ´Â °³¹ß µµ»ó Áö¿ª¿¡ °³¹ß ±âȸ°¡ ź»ýÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß ¹× Àü·«Àû Á¦ÈÞ¿¡ ÅõÀÚÇÏ´Â ±â¾÷Àº ½ÃÀå Á¡À¯À² ȹµæ¿¡ À¯¸®ÇÑ ÀÔÀå¿¡ ÀÖ½À´Ï´Ù. TIL Ä¡·á ½ÃÀåÀº È¿°úÀûÀÎ ¾Ï Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó ¾ÕÀ¸·Îµµ È®´ë°¡ °è¼ÓµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼ºÀå ¾ïÁ¦¿äÀÎ ¹× °úÁ¦ :

TIL Ä¡·á ½ÃÀå¿¡´Â ¸î °¡Áö Áß¿äÇÑ ¾ïÁ¦¿äÀÎ ¹× °úÁ¦°¡ ÀÖ½À´Ï´Ù. ÁÖ¿ä °úÁ¦´Â ³ôÀº Á¦Á¶ ¹× °³¹ß ºñ¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦Àû ºÎ´ãÀº ƯÈ÷ ½ÅÈï ½ÃÀå¿¡¼­ÀÇ Á¢±Ù¼º°ú È®À强À» Á¦ÇÑÇÕ´Ï´Ù. °Ô´Ù°¡ ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú ±ä ½ÂÀÎ °úÁ¤Àº »õ·Î¿î Ä¡·á¹ýÀÇ µµÀÔÀ» ´ÊÃß°í Çõ½Å°ú ½ÃÀå ħÅõ¸¦ ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ¿ì·Á´Â TIL Ä¡·áÀÇ º¹ÀâÇÑ ¹°·ùÀ̸ç Àü¹® ½Ã¼³°ú ¼÷·ÃµÈ ÀηÂÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺Àº ¿î¿µ ºñ¿ëÀ» Áõ°¡½ÃŰ°í º¸±ÞÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, TIL Ä¡·áÀÇ Àå±âÀûÀÎ È¿´É°ú ¾ÈÀü¼ºÀ» µÞ¹ÞħÇÏ´Â Á¾ÇÕÀûÀÎ ÀÓ»ó µ¥ÀÌÅͰ¡ ºÎÁ·ÇÏ¿© ÅõÀÚ¿Í È¯ÀÚÀÇ ¼ö¿ëÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¶ÇÇÑ CAR-T ¹× üũÆ÷ÀÎÆ® ¾ïÁ¦Á¦¿Í °°Àº ´ëü ¸é¿ª Ä¡·á¿ÍÀÇ Ä¡¿­ÇÑ °æÀï¿¡ ½Ã´Þ¸®°í ÀÖÀ¸¸ç, TIL Ä¡·áÀÇ ±×¸²ÀÚ°¡ Èñ¹ÌÇØÁú ¼ö ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ÀÓ»ó½ÃÇè¿¡¼­ ȯÀÚ¸¦ ¸ðÁýÇÏ´Â °ÍÀº ¿©ÀüÈ÷ ¾î·Á¿òÀ̸ç, Á¾Á¾ ¾ö°ÝÇÑ ÀÚ°Ý ±âÁØÀÌ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºêÀÇ ¼Óµµ¿Í ¼º°ø¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

ÁÖ¿ä ±â¾÷

Iovance Biotherapeutics, Adaptimmune Therapeutics, Kite Pharma, Immunocore, Turnstone Biologics, Tmunity Therapeutics, Cellectis, Autolus Therapeutics, Fate Therapeutics, Atara Biotherapeutics, Neogene Therapeutics, Instil Bio, Marker Therapeutics, Gritstone Oncology, Ziopharm Oncology

¸ñÂ÷

Á¦1Àå TIL Ä¡·á ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå¿¡ °üÇÑ Áß¿ä ÀλçÀÌÆ®

Á¦4Àå TIL Ä¡·á ½ÃÀå Àü¸Á

Á¦5Àå TIL Ä¡·á ½ÃÀå Àü·«

Á¦6Àå TIL Ä¡·á ½ÃÀå ±Ô¸ð

Á¦7Àå TIL Ä¡·á ½ÃÀå ±Ô¸ð : À¯Çüº°

Á¦8Àå TIL Ä¡·á ½ÃÀå : Á¦Ç°º°

Á¦9Àå TIL Ä¡·á ½ÃÀå : ¼­ºñ½ºº°

Á¦10Àå TIL Ä¡·á ½ÃÀå : ±â¼úº°

Á¦11Àå TIL Ä¡·á ½ÃÀå : ¿ëµµº°

Á¦12Àå TIL Ä¡·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦13Àå TIL Ä¡·á ½ÃÀå : ÇÁ·Î¼¼½ºº°

Á¦14Àå TIL Ä¡·á ½ÃÀå : ½ºÅ×ÀÌÁöº°

Á¦15Àå TIL Ä¡·á ½ÃÀå : ¼Ö·ç¼Çº°

Á¦16Àå TIL Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦17Àå °æÀï ±¸µµ

Á¦18Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

TIL Therapy Market is anticipated to expand from $0.4 billion in 2024 to $6.1 billion by 2034, growing at a CAGR of approximately 31.3%. The TIL Therapy Market encompasses treatments utilizing tumor-infiltrating lymphocytes, which are immune cells extracted from a patient's tumor, expanded in vitro, and reinfused to target cancer cells. This personalized immunotherapy aims to enhance the body's natural anti-tumor response. Increasing cancer prevalence and advancements in cell therapy technologies are propelling market growth, with a focus on improving efficacy, reducing costs, and expanding clinical applications.

The TIL Therapy Market is experiencing robust expansion, driven by advancements in personalized cancer treatment approaches. The melanoma segment leads in performance, owing to its higher responsiveness to TIL therapy and extensive research backing. Non-small cell lung cancer (NSCLC) follows as the second-highest performing segment, benefiting from increasing clinical trials and promising preliminary results. Within the melanoma sub-segment, early-stage interventions are showing significant promise, enhancing patient outcomes and survival rates. Advanced-stage treatments are also gaining traction, driven by a growing body of successful case studies. In the NSCLC sub-segment, patients with specific genetic markers are emerging as prime beneficiaries, thanks to targeted therapy advancements. Research and development investments are critical in propelling the market forward, with a focus on improving TIL harvesting techniques and enhancing cell expansion processes. As regulatory landscapes evolve, streamlined approval pathways are expected to accelerate market growth, fostering innovation and expanding therapeutic options.

Market Segmentation
TypeAutologous TIL Therapy, Allogeneic TIL Therapy
ProductCell Culture Media, Reagents and Kits, Instruments, Software
ServicesManufacturing, Quality Control, Consulting, Logistics
TechnologyGenetic Engineering, Cell Expansion, Cryopreservation, Bioreactors
ApplicationOncology, Hematology, Solid Tumors, Rare Diseases
End UserHospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
ProcessIsolation, Expansion, Activation, Infusion
StagePreclinical, Clinical, Commercial
SolutionsTurnkey Solutions, Custom Solutions, Integrated Solutions

Market Snapshot:

The TIL Therapy Market is witnessing a dynamic landscape, characterized by evolving market shares and strategic pricing models. New product launches are invigorating the market, driven by advancements in immunotherapy technologies. Companies are focusing on innovative treatments that enhance patient outcomes. This competitive environment encourages firms to differentiate through unique offerings and strategic collaborations. Pricing strategies are increasingly influenced by value-based models, reflecting the emphasis on cost-effectiveness and patient-centric care. The competitive landscape of the TIL Therapy Market is marked by intense rivalry among key players. Companies are engaging in benchmarking to maintain a competitive edge, leveraging technological innovations and strategic partnerships. Regulatory frameworks significantly influence market dynamics, with stringent guidelines shaping product development and approval processes. The regulatory landscape in North America and Europe is particularly impactful, dictating market entry and expansion strategies. As the market evolves, regulatory compliance and strategic agility remain crucial for sustained growth and competitiveness.

Geographical Overview:

The TIL Therapy market is witnessing a notable expansion across various regions, each presenting unique growth opportunities. North America currently leads the market, propelled by robust investments in biotechnology and advanced cancer treatment modalities. The presence of leading biotech firms and research institutions further bolsters the region's dominance. Europe follows closely, driven by significant research funding and a strong emphasis on innovative cancer therapies. The region's regulatory support for novel treatments enhances its market prospects. In Asia Pacific, the market is rapidly growing, supported by increasing healthcare expenditure and advancements in medical research. Countries like China and India are emerging as key players due to their expanding biotech sectors and supportive government policies. Latin America and the Middle East & Africa are also showing promising growth potential. In Latin America, rising healthcare investments are fostering market expansion, while in the Middle East & Africa, increasing awareness and adoption of advanced therapies are driving market growth.

Key Trends and Drivers:

The TIL Therapy Market is experiencing robust growth, propelled by advancements in personalized medicine and immunotherapy. These therapies are gaining traction due to their potential to target specific cancer cells, minimizing damage to healthy tissues. Researchers are focusing on enhancing TIL therapy efficacy, leveraging genetic engineering and combination therapies. Additionally, increased investment in biotechnology and cancer research is driving market expansion. Governments and private entities are funding initiatives to develop innovative cancer treatments. This financial support is accelerating clinical trials and regulatory approvals, thereby boosting market dynamics. Rising cancer prevalence globally is also a significant market driver. Patients and healthcare providers are increasingly adopting TIL therapies due to their promising clinical outcomes. The trend towards precision medicine is further augmenting market growth. Opportunities are emerging in developing regions where healthcare infrastructure is improving. Companies investing in R&D and strategic collaborations are well-positioned to capture market share. The TIL Therapy Market is poised for continued expansion as demand for effective cancer treatments rises.

Restraints and Challenges:

The TIL Therapy Market encounters several significant restraints and challenges. A predominant challenge is the high cost of manufacturing and development. This financial burden limits accessibility and scalability, particularly in emerging markets. Additionally, regulatory hurdles and lengthy approval processes can delay the introduction of new therapies, stifling innovation and market penetration. Another concern is the complex logistics of TIL therapy, which require specialized facilities and skilled personnel. This complexity can increase operational costs and limit widespread adoption. Furthermore, there is a scarcity of comprehensive clinical data supporting the long-term efficacy and safety of TIL therapies, which can deter investment and patient acceptance. The market also grapples with intense competition from alternative immunotherapies, such as CAR-T and checkpoint inhibitors, which can overshadow TIL therapies. Lastly, patient recruitment for clinical trials remains a challenge, often due to stringent eligibility criteria, affecting the speed and success of research initiatives.

Key Players:

Iovance Biotherapeutics, Adaptimmune Therapeutics, Kite Pharma, Immunocore, Turnstone Biologics, Tmunity Therapeutics, Cellectis, Autolus Therapeutics, Fate Therapeutics, Atara Biotherapeutics, Neogene Therapeutics, Instil Bio, Marker Therapeutics, Gritstone Oncology, Ziopharm Oncology

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: TIL Therapy Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: TIL Therapy Market Outlook

5: TIL Therapy Market Strategy

6: TIL Therapy Market Size

7: TIL Therapy Market, by Type

8: TIL Therapy Market, by Product

9: TIL Therapy Market, by Services

10: TIL Therapy Market, by Technology

11: TIL Therapy Market, by Application

12: TIL Therapy Market, by End User

13: TIL Therapy Market, by Process

14: TIL Therapy Market, by Stage

15: TIL Therapy Market, by Solutions

16: TIL Therapy Market, by Region

17: Competitive Landscape

18: Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â